Rexahn Pharmaceuticals, Inc. (REXN) financial statements (2021 and earlier)

Company profile

Business Address 37000 GRAND RIVER AVE.
FARMINGTON HILLS, MI 48335
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:1612927202333
Cash and cash equivalents16999121010
Short-term investments   1891323
Other undisclosed cash, cash equivalents, and short-term investments 3     
Prepaid expense1 11010
Other current assets0011010
Other undisclosed current assets 06    
Total current assets:18131628212533
Noncurrent Assets
Property, plant and equipment0000000
Other undisclosed noncurrent assets 000000
Total noncurrent assets:0000000
TOTAL ASSETS:18131628212534
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:3133232
Accounts payable1      
Accrued liabilities2      
Other undisclosed accounts payable and accrued liabilities 133232
Contract with customer, liability2 
Other undisclosed current liabilities 0     
Total current liabilities:3333232
Noncurrent Liabilities
Liabilities, other than long-term debt  00000
Deferred revenue and credits0000
Deferred rent credit  0
Other undisclosed noncurrent liabilities280     
Total noncurrent liabilities:28000000
Other undisclosed liabilities  28234
Total liabilities:313512467
Stockholders' equity
Stockholders' equity attributable to parent(13)101117171927
Common stock0000000
Treasury stock, value      (0)
Additional paid in capital19173165157132124118
Accumulated other comprehensive income (loss) 0(0)(0)(0)(0)(0)
Accumulated deficit(33)(163)(155)(140)(115)(106)(91)
Total stockholders' equity:(13)101117171927
TOTAL LIABILITIES AND EQUITY:18131628212534

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Gross profit: 3     
Operating expenses(20)(11)(21)(17)(16)(18)(13)
Other undisclosed operating loss (3)     
Operating loss:(20)(11)(21)(17)(16)(18)(13)
Nonoperating income (expense)(1)36(8)74(5)
Investment income, nonoperating(1)000000
Interest and debt expense(3)  (1)(0)(0)(0)
Net loss:(25)(9)(14)(26)(10)(15)(19)
Other undisclosed net income attributable to parent   1000
Net loss available to common stockholders, diluted:(25)(9)(14)(25)(9)(14)(19)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss:(25)(9)(14)(26)(10)(15)(19)
Comprehensive loss:(25)(9)(14)(26)(10)(15)(19)
Other undisclosed comprehensive income, net of tax, attributable to parent 001000
Comprehensive loss, net of tax, attributable to parent:(25)(9)(14)(25)(9)(14)(19)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: